CompletedEUCTR 2018-001444-66
ASSESSING TOLERABILITY AND EFFICACY OF VORTIOXETINE VERSUS SSRIs IN ELDERLY PATIENTS WITH DEPRESSION: A PRAGMATIC, MULTICENTER, OPEN-LABEL, PARALLEL-GROUP, SUPERIORITY, RANDOMIZED TRIAL
This historical record does not confirm current site availability.
Historical research recordItaly
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- Italy
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 358
- Sponsor
- AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Italy
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2018-001444-66
- Official title
Show the full official title
ASSESSING TOLERABILITY AND EFFICACY OF VORTIOXETINE VERSUS SSRIs IN ELDERLY PATIENTS WITH DEPRESSION: A PRAGMATIC, MULTICENTER, OPEN-LABEL, PARALLEL-GROUP, SUPERIORITY, RANDOMIZED TRIAL
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Italy
Registry details
Historical country statuses
- Italy — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depressio...
A long term open label, flexiable dose, extension study evaluationg the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder